RA
Rosalind Advisors Portfolio holdings
AUM
$207M
This Quarter Return
+12.68%
1 Year Return
+62.29%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$107M
AUM Growth
+$107M
(-11%)
Cap. Flow
-$13.7M
Cap. Flow
% of AUM
-12.84%
Top 10 Holdings %
Top 10 Hldgs %
58.36%
Holding
41
New
11
Increased
2
Reduced
11
Closed
7
Top Buys
| 1 |
CYBN
Cybin
CYBN
|
$5.77M |
| 2 |
ABVX
Abivax
ABVX
|
$5.41M |
| 3 |
Clearside Biomedical
CLSD
|
$3.97M |
| 4 |
Outlook Therapeutics
OTLK
|
$3.72M |
| 5 |
Unicycive Therapeutics
UNCY
|
$2.59M |
Top Sells
| 1 |
Astria Therapeutics
ATXS
|
$8.67M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$5.78M |
| 3 |
Sarepta Therapeutics
SRPT
|
$5.54M |
| 4 |
Cellectar Biosciences
CLRB
|
$5.51M |
| 5 |
Lyra Therapeutics
LYRA
|
$4.63M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Myomo
MYO
$39.7M
| $8M | 7.48% | 2,447,740 +527,830 | +27% | +$1.73M |
|
|
2
Lyra Therapeutics
LYRA
$11.5M
| $7.12M | 6.65% | 1,144,524 -744,196 | -39% | -$4.63M |
|
3
MediWound
MDWD
$182M
| $6.93M | 6.47% | 485,990 -120,761 | -20% | -$1.72M |
|
|
OPTN
4
DELISTED
OptiNose
OPTN
| $6.63M | 6.2% | 4,541,489 -344,091 | -7% | -$502K |
|
5
Xeris Biopharma Holdings
XERS
$1.26B
| $6.23M | 5.82% | 2,820,170 -723,515 | -20% | -$1.6M |
|
|
CMPS
6
Compass Pathways
CMPS
$424M
| $6.11M | 5.71% | 734,000 -64,500 | -8% | -$537K |
|
|
CYBN
7
Cybin
CYBN
$176M
| $5.77M | 5.39% | +13,960,000 | New | +$5.77M |
|
|
ABVX
8
Abivax
ABVX
$6.12B
| $5.41M | 5.06% | +378,416 | New | +$5.41M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $5.25M | 4.91% | 300,000 -60,332 | -17% | -$1.06M |
|
10
Delcath Systems
DCTH
$385M
| $4.96M | 4.63% | 1,038,828 | – | – |
|
|
PROF
11
Profound Medical
PROF
$134M
| $4.55M | 4.25% | 533,333 | – | – |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $4.02M | 3.76% | 250,000 | – | – |
|
|
13
Clearside Biomedical
CLSD
$28.9M
| $3.97M | 3.71% | +2,592,593 | New | +$3.97M |
|
|
14
Outlook Therapeutics
OTLK
$37.8M
| $3.72M | 3.48% | +311,775 | New | +$3.72M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $3.42M | 3.19% | 287,985 -12,015 | -4% | -$142K |
|
16
Trevi Therapeutics
TRVI
$883M
| $3.19M | 2.99% | 926,016 -936,409 | -50% | -$3.23M |
|
17
Veru
VERU
$47.6M
| $3.15M | 2.94% | 4,500,000 +500,000 | +13% | +$350K |
|
|
18
Unicycive Therapeutics
UNCY
$74M
| $2.59M | 2.42% | +1,879,646 | New | +$2.59M |
|
|
19
Cellectar Biosciences
CLRB
$15.5M
| $2.47M | 2.31% | 621,478 -1,384,180 | -69% | -$5.51M |
|
20
PolyPid
PYPD
$53.3M
| $1.91M | 1.79% | +415,800 | New | +$1.91M |
|
21
InspireMD
NSPR
$102M
| $1.63M | 1.52% | 686,062 -239,132 | -26% | -$567K |
|
22
Kiora Pharmaceuticals
KPRX
$9.55M
| $1.62M | 1.52% | +2,300,000 | New | +$1.62M |
|
23
Beyond Air
XAIR
$11.6M
| $1.57M | 1.47% | +903,614 | New | +$1.57M |
|
|
TVRD
24
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $1.41M | 1.32% | +1,548,893 | New | +$1.41M |
|
25
Fortress Biotech
FBIO
$76.8M
| $1.22M | 1.14% | 607,797 | – | – |
|